Newcastle University

Research Interests

MECHANISMS OF DRUG TOXICITY. My current main interest lies with the elucidation of the mechanisms of toxicity associated with anticoagulation therapy. The Group aims to elucidate risks and benefits of anticoagulation in older people and to achieve appropriate clinical strategies for prevention and treatment of thromboembolic disease.

Other Expertise

EXPERIMENTAL THERAPEUTICS. This aspect of my research involves investigations into human pharmacology and pharmacokinetics of new therapeutic agents, investigations of their primary and secondary pharmacological properties and of their potential interactions with other drugs that may be co-administered during therapy.

EPIDEMIOLOGY OF ALCOHOL AND DRUG MISUSE IN YOUNG PEOPLE. I have a keen interest in research evaluating substance and alcohol misuse among young people. This research began on the basis of my interest on toxicological and addictive issues relating to alcohol and illicit drugs and their growing use among young people.

Keywords

Thormbosis, anticoagulation, warfarin, vitamin K, ageing

Undergraduate Teaching

BSC Pharmacology & biomedical sciences
MBBS

• Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur APA, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Körtke H, Levi M, Matchar D, Menéndez-Jándula B, Rakovac I, Schaefer C, Siebenhofer-Kroitzsch A, Souto JC, Sunderji R, Gin G, Shalansky K, Völler H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379(9813), 322-334.
• Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology 2012, 73(1), 66-76.
• Biss TT, Avery PJ, Walsh PM, Kamali F. Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal]. Journal of Thrombosis and Haemostasis 2011, 9(11), 2332-2333.
• Fairbairn-Smith L, Cope W, Robinson B, Kamali F, Wynne H. Effect of provision of the NHS NPSA oral anticoagulant therapy patient information pack upon patients' knowledge and anticoagulant control. Journal of Thrombosis and Haemostasis 2011, 9(1), 231-233.
• Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F, on behalf of the EU-PACT Study Group. Proposal for an individualised pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clinical Pharmacology and Therapeutics 2011, 90(5), 701-706.
• Biss TT, Adamson AJ, Seal CJ, Kamali F. The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin. Pediatric Hematology and Oncology 2011, 28(5), 425-427.
• Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2011, 119(3), 868-873.
• Biss TT, Avery PJ, Walsh PM, Kamali F. Warfarin treatment outcomes in children monitored at home with a point-of-care device. Thrombosis and Haemostasis 2011, 105(6), 1103-1105.
• Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Sarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, on behalf of the International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010, 115(18), 3827-3834.
• Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thrombosis and Haemostasis 2005, 93(5), 872-875.
• Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology and Therapeutics 2004,75 3 204-212.
• Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. The effect of dietary vitamin K upon intra-individual variability in anticoagulantion response to warfarin.. 2004.British Journal of Haematology, 124, 348-354.
• Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. British Journal of Haematology 2004,126 4 557-564.
• King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics 2004,14 12 813-822.
• Kamali F. [Book Review] Introduction to drug metabolism. British Journal of Clinical Pharmacology 2003, 56(3), 345.
• King BP, Khan T, Kamali F, Daly AK. Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements. In: Drug Metabolism Reviews: 8th European Meeting of the International Society for the Study of Xenobiotics (ISSX). 2003, Dijon, France: Informa Healthcare.
• Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thrombosis and Haemostasis 2003. ,89 5 949-950.
• Jaffary F, Khan T, Wynne HA, Kesteven PJ, Kamali F. The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life. Journal of the American Geriatrics Society 2003,51 6 885-887.
• Khan T, Kamali F, Daly A, King B, Wynne HA. Warfarin sensitivity: Be aware of genetic influence. Age and Ageing 2003,32 2 226-227.
• Siccardi D, Kamali F. Stereoselectivity in thioridazine metabolism in vitro. British Journal of Clinical Pharmacology 2002, 53(4), 445P.
• Newbury-Birch D, Lowry RJ, Kamali F. The changing pattern of drinking, illicit drug use, stress, anxiety and depression in dental students: a longitudinal study (authors reply). British Dental Journal 2002, 193(5), 244.
• Webb J, Rostami-Hodjegan A, Abdul-Manap R, Mikus G, Hofman U, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a Pk-PD modelling analysis. British Journal of Clinical Pharmacology 2001, 52(1), 35-43.
• Newbury-Birch D, Walshaw D, Kamali F. Drink and drugs: From medical students to doctors. Drug and Alcohol Dependence 2001, 64(3), 265-270.
• Kamali F. Osanetant Sanofi-Synthélabo. Current Opinion in Investigational Drugs 2001, 2(7), 950-956.
• Newbury-Birch D, Kamali F. Psychological stress, anxiety, depression, job satisfaction, and personality characteristics in preregistration house officers. Postgraduate Medical Journal 2001, 77(904), 109-111.
• Kamali F, Edwards C, Wood P, Wynne HA, Kesteven P. Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans. American Journal of Hematology 2001, 68(3), 159-163.
• Kamali F. Almotriptan Almirall Prodesfarma SA. Current Opinion in CPNS Investigational Drugs 2000, 2, 197-202.
• Kamali F. Apomorphine, sublingual (TAP Pharmaceuticals). Current Opinion in Central and Peripheral Nervous System Investigational Drugs 2000, 2(3), 303-310.
• Kamali F, Edwards C, Butler TJ, Wynne HA. The contribution of plasma (R)- and (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation. Thrombosis and Haemostasis 2000, 83(2), 349-350.
• Kamali F, Edwards C, Butler TJ, Wynne HA. The influence of (R)- and (S)-Warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thrombosis and Haemostasis 2000, 84(1), 39-42.
• Kamali F. BMS-181885-Bristol Myers Squibb. Current Opinions in CPNS Investigational Drugs 1999, 1, 98-101.
• Kamali F. Ditropan XL ALZA Corp. IDrugs 1999, 2(4), 360-365.
• Kamali F. Ditropan-XL-Alza Corp. Current Opinions in CPNS Investigational Drugs 1999, 1, 278-283.
• Kamali F. KMD-3213-Kissei Pharmaceutical Co Ltd. Current Opinions in CPNS Investigational Drugs 1999, 1, 248-252.
• Kamali F. Rofecoxib- Merck & Co Inc. Current Opinions in CPNS Investigational Drugs 1999, 1, 126-131.
• Kamali F. Talsaclidine fumarate-Boehringer Ingelheim Corp. Current Opinions in CPNS Investigational Drugs 1999, 1, 373-377.
• Kamali F, Ball DE, Mcloughlin WS and Seymour RA. The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth. J Clin Perio 1999, 26, 802-805.
• Birch D, Ashton H, Kamali F. Alcohol drinking, illicit drug use and stress in junior house officers in the north east of England. Lancet 1998, 352, 785-786.
• Webb E, Ashton CH, Kelly P, Kamali F. Alcohol and drug use in UK university students. Lancet 1996, 384, 922-925.